A leading provider of &39.

Many have been validated in its sector leading portfolio of rigorous, peer-reviewed, published clinical studies. These document improvements in HbA1c levels among individuals with diabetes by 1.8 points; improvements in blood pressure levels for patients with hypertension by 11/6 mmHg; reductions in all-cause hospital readmissions by 20 %; and reductions in costs of look after patients with heart failing by $2,592 per patient per year, delivering a program ROI of 3.3 to 1 1. AMC Health's Remote Individual Monitoring and Engagement Solutions have also earned the exclusive endorsement of the American Hospital Association. As telehealth-based solutions accelerate the transformation of chronic population and care health management, URAC has identified the need to establish national criteria and effective quality steps for these ongoing solutions.Alnara to announce Phase 3 study outcomes of liprotamase for treating cystic fibrosis at the 23rd NACFC Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered proteins therapeutics for the treating metabolic diseases, today that results from a landmark announced, international Phase 3 study of the long-term safety and nutritional great things about liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis will be offered at the 23rd Annual UNITED STATES Cystic Fibrosis Meeting being kept October 15-17, 2009 in Minneapolis, Minnesota. Liprotamase is being created in collaboration with the Cystic Fibrosis Base Therapeutics, Inc.